Total Voting Rights
Following this transaction, the total number of Ordinary Shares in issue at today's date is 99,749,762 and following this transaction, the total number of Ordinary Shares held as treasury shares by the Company is 26,063,262 (which includes the 9,544,500 shares purchased by the Company since 15 December 2023 which are pending cancellation). Therefore, the total number of voting rights in the Company is 73,686,500 which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
That appears to be a 26% reduction in the total number of shares once all shares held in treasury are cancelled ... |
Yeah hopefully now we might get see 100 again |
They bought back 2% of the outstanding shares yesterday. |
That final line is truly shocking. Since 1993, obese proportion up from 14.9% to 28%. One in seven becomes two in seven. |
 Slightly more scientific appraisal of Morphic Medicals EndoBarrierPresented by Bob Ryderhttps://abcd.care/committee-member/756He leads the ABCD nationwide audits of new therapies and devices"EndoBarrier is currently not approved in the United States. It is awaiting United Kingdom and European CE mark, which the manufacturer hope will be granted this summer. The license will be for patients with BMI of 35-50 kg/m2."https://www.medscape.com/viewarticle/temporary-gut-liner-lowers-weight-a1c-2024a10007kvIt does seem given approval and the scale of the problem that the success in the treatment avoiding medication or major surgery could well be a tool in the tools used in longer term weight loss in a significant number of cases.Severely Obese (Class II) 35 39.9Morbidly Obese (Class III) ?40Since 1993 the proportion of adults in England who are overweight or obese has risen from 52.9% to 64.3%, and the proportion who are obese has risen from 14.9% to 28.0%.https://commonslibrary.parliament.uk/research-briefings/sn03336/ |
Bernstein tweet ..seems Morphic getting some attention.https://x.com/crystalamberrb1/status/1780850453560889721?s=61&t=s79RLRddG_Gfl7VpUZvZpQDirect link to article https://www.dailymail.co.uk/health/article-13318639/gut-liner-patients-feel-quickly-lose-weight.html |
Morphic got a brief mention in this review:
Metabolic Endoscopy: Should Gastroenterologists Be Treating
Type 2 Diabetes?
CRS have most of their eggs in that basket. |
I set an alert for 85p ages ago .... just got triggered.
Director's Dealings?
Crystal Amber Fund was notified on 26 February 2024 that the Investment Manager, Crystal Amber Asset Management (Guernsey) Limited, a PDMR of the Company, sold 600,000 Ordinary Shares in the Company on 26 February 2024. Following this transaction, Crystal Amber Asset Management (Guernsey) Limited holds 6,299,031 Ordinary Shares (equivalent to 8.16 per cent. of the Company's voting rights). |
There are five trading days up to and including next Tuesday and up to last night about half the £5 million had been spent.
Since the AGM motion authorised repurchases up to 15% of capital they are not close to that limit so it could restart again should the share price drop back after they spend the remaining £2.5 million. They just need to find a few more quid down the cushions. The authorisation remains until the 2024 GM.
Any sign of movement in DLAR, Prax or Morphic? Just musing ... |
I've always believed they would have to include a discounted value of the possible future revenue streams in NAV for the DCUs. That was originally anything from zero up to an additional 2.98 pence per share eventually (based on hope/guesswork) of which they have only had 0.309 pence so far. £0.00309 times 575 million is the £1.8 million.
They need Prax to find a project to produce Lancaster profits to get it up the 2.98 pps. I don't know if they have. If they do find one it should help the discounted value.
Question for the Board though. |
I've sold out now. The discount to NAV is still large but the temporary buyback is at an end - which seemed to give a big push to the recent price rise. Will wait and see.
GLA |
Thanks for your answer @wbodger but I mean all the future payments that have been agreed but not yet paid. Must be a considerable amount. |
Yes, paid in September or October. The next one is due in March. The September payment was £1.8 million. (See Chairman's report in Results for year ending June 2023, announced 25 October 2023. Says £1.8 million was "banked" earlier in the month.) |
Does the CRS NAV include expected payments from PRAX? |
End-December NAV 106.08 pence(30 November 2023: 99.6 pence per share).
Effect of improvement in DLAR shareprice I suppose. Shares bought for 79 pence are at a 25% discount to intrinsic value per CA. |
79p now being paid for shares.
oh yeah :) |
All about the current share but back.
£5m can be spent up to the 30th Jan.
5 weeks!
£5m is a whack of buying pressure imo. |
55p since the beginning of last year |
Does this fund pay a dividend? |
^sort of puts a floor under the share price IMO.
Not a bad thing.. :0)
£5m protection to the downside. |
hmm, they can only buy at 105% of the middle market position for the five previous days.
I reckon the recent price is about 63p so they can only buy up to 66p at the moment. topped up with another chunk today.
Buy back could kick in by mid way through next week if 66p holds |
I'm pleasantly surprised that they are doubling down on their estimate of NAV. DLAR has been strong but there is only Morphic to make up the difference between the claimed NAV and the market share price Allied Minds could surprise I suppose but not more than 5 to 10 pence with a very fair wind. DLAR getting an offer would be very helpful. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
